ADMET and DMPK, Vol. 14 , 2026.
Pregledni rad
https://doi.org/10.5599/admet.3030
Precision therapeutics in non-scarring alopecia: a systemic genomic and pathway-based framework for targeted interventions
Rinky Kapoor
; Department of Dermatology, Cosmetic Dermatology & Dermato-Surgery, The Esthetic Clinics, Mumbai, Maharashtra, India
Depti Bellani
; Department of Medical Affairs, The Esthetic Creations International Pvt. Ltd. (ECIPL), Mumbai, Maharashtra, India
Raji Patil
; Department of Medical Affairs, The Esthetic Creations International Pvt. Ltd. (ECIPL), Mumbai, Maharashtra, India.
Debalina Bose
orcid.org/0009-0005-0350-3839
; Department of Research, The Esthetic Clinics Clinical Research Organization (TECCRO), Mumbai, Maharashtra, India
Madhuri Pola
; Department of Research, The Esthetic Clinics Clinical Research Organization (TECCRO), Mumbai, Maharashtra, India
Prashant Anilkumar Singh
; Department of Medical Affairs, The Esthetic Creations International Pvt. Ltd. (ECIPL), Mumbai, Maharashtra, India
Mamata Mishra
; Department of Research, The Esthetic Clinics Clinical Research Organization (TECCRO), Mumbai, Maharashtra, India
Debraj Shome
; Department of Facial Plastic Surgery & Facial Cosmetic Surgery, The Esthetic Clinics, Mumbai, Maharashtra, India
*
* Dopisni autor.
Sažetak
Background and purpose: Non-scarring alopecia, principally androgenetic alopecia and alopecia areata is highly prevalent and psychologically burdensome; androgenetic alopecia is androgen-driven, whereas alopecia areata is autoimmune. This review synthesizes genetic architecture and pathway biology to outline a precision framework for targeted interventions. Experimental approach: We reviewed full-text studies from the past decade across PubMed, Web of Science and Google Scholar, applying explicit inclusion/exclusion criteria; emphasis was placed on Genome wide association studies and Next generation sequencing findings, immune and androgen-axis biology, environmental modifiers, and therapeutic evidence (conventional, targeted, and regenerative), alongside artificial Intelligence-enabled diagnostics. Key results: Androgenetic alopecia risk converges on androgen-receptor signalling and related loci, with perifollicular inflammation and oxidative stress as modifiers; finasteride remains a cornerstone therapy. Alopecia areata reflects polygenic immune dysregulation (e.g. Human leukocyte antigen/cytokine axes) with Janus Kinase-pathway inhibition yielding robust regrowth; across phenotypes, wingless-related integration sit/β-catenin and stem-cell programs are central targets. Regenerative options (Protein Rich Plasma, stem-cell/exosome approaches) and artificial Intelligence-assisted stratification are emerging adjuncts. Conclusion: A pathway-guided, genotype and phenotype-informed strategy, targeting the androgen axis for androgenetic alopecia, immune circuits for alopecia areata, and adding regenerative or microenvironmental therapies where indicated-promises earlier diagnosis and more durable, individualized outcomes, especially as genome-wide association study/next-generation sequencing and artificial Intelligence tools are integrated into care.
Ključne riječi
Androgenetic alopecia; alopecia areata; genome-wide association studies and next-generation sequencing; wingless-related integration sit/beta-catenin signalling pathway; Janus kinase-signal transducer and activator of transcription pathway; artificial intelligence
Hrčak ID:
345195
URI
Datum izdavanja:
16.12.2025.
Posjeta: 282 *